Outlook Wealth Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Outlook Wealth Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-7,869	Closed	-$895K	–	209
2022 Q4	$895K	Sell	7,869 -154	-2%	-$12.8K	0.43%	58
2022 Q3	$496K	Buy	8,023 +27	+0.3%	+$1.89K	0.22%	112
2022 Q2	$637K	Buy	7,996 +189	+2%	+$17.9K	0.26%	100
2022 Q1	$822K	Sell	7,807 -56	-0.7%	-$5.46K	0.27%	90
2021 Q4	$847K	Buy	7,863 +228	+3%	+$24.9K	0.25%	96
2021 Q3	$836K	Buy	7,635 +126	+2%	+$13.1K	0.27%	92
2021 Q2	$703K	Buy	7,509 +4	+0.1%	+$368	0.22%	108
2021 Q1	$691K	Sell	7,505 -613	-8%	-$51.7K	0.24%	99
2020 Q4	$594K	Buy	8,118 +128	+2%	+$9.51K	0.22%	113
2020 Q3	$621K	Buy	+7,990	New	+$550K	0.25%	89

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Outlook Wealth Advisors's HZNP Position: Q1 2023 in Review

Outlook Wealth Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 7,869 shares — an estimated $895K sold.

Outlook Wealth Advisors first reported a position in HZNP in Q3 2020 and held it in 10 quarters. The position peaked at $895K in Q4 2022. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

Outlook Wealth Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Outlook Wealth Advisors sold 7,869 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $895K.
Outlook Wealth Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2020 and held it in 10 quarters.
Outlook Wealth Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $895K in Q4 2022.
553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Outlook Wealth Advisors's 13F filing for Q1 2023, filed 18 Apr 2023.